Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: czycz who wrote (19019)	2/23/1999 2:17:00 AM
From: VLAD	Respond to of 23519

<<How long is long enough?>> It has been way too long. I initially got into Vivus over a year ago looking for a move from the 11 to 13 range back into the high teen low twenties. Hell is starting to freeze over and here we are at a whopping 2 9/32 after over one year of sitting on this stock! I think that it is wrong to just look at gene therapy. Its time will come but I think in the mean time Vivus can have some nice earnings from MUSE/Alibra in the next 3 to 5 years. By then gene therapy will be a reality and who knows what other drugs may be employed via the intraurethral route. Bottom line is that in the short term we need to see something in terms of earnings. We know that milestones are a sure thing in the next 1 to 4 months and European product sales are a sure thing in the second 1/2 of 1999. That being said I still do not understand how we justify a sub $3.00 stock. I guess in the shorter term a domestic partner announcement is what everyone really wants to guarantee increased domestic product sales. What the hell does Wilson spend his days doing? Does he count paper clips in his desk drawer for 350k/year? He certainly couldn't have been in serious negotiations the past 8 months--otherwise I would have expected a signed document by now.